First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope: Duarte
Duarte, California, United States
- Iu Health Goshen Hospital
Goshen, Indiana, United States
- Iu Health Central Indiana Cancer Centers
Indianapolis, Indiana, United States
- Indiana University Melvin & Bren Simon Cancer Center
Indianapolis, Indiana, United States
- Nebraska Cancer Specialists
Omaha, Nebraska, United States
- Tisch Cancer Institute at Mount Sinai Medical Center
New York, New York, United States
- Texas Oncology, Pa
Dallas, Texas, United States
- Virginia Oncology Associates
Norfolk, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jan 2012
- Primary completion
- 15 Jul 2017
- Completion
- 31 Dec 2018
- Last update posted
- 11 Jul 2022
- Registered enrollment
- 36
- Registry id
- NCT01524991
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.